Loading…
Loading…
MLEC does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MLEC and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MLEC and 80,000+ other tickers.
See exactly how MLEC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MLEC and 80,000+ other tickers.
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas. The company is based in Grand Cayman, Cayman Islands.
WARWICK, GB / ACCESS Newswire / May 14, 2026 / Moolec Science Limited, a wholly owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced the successful completion of the 2026 commercial planting campaign for its GLASO1 safflower program focused on the production of high-GLA ("Gamma-Linolenic Acid") specialty oils for industrial and advanced ingredient applications. "Today represents a defining moment for Moolec.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / May 13, 2026 / As previously reported on January 29, 2026, Moolec Science SA ("Moolec" and/or the "Company"), received written notice from the Nasdaq Hearings Panel (the "Panel") informing the Company that the Panel had granted the Company's request for an extension to regain compliance with the continued listing requirements of The Nasdaq Stock Market LLC, specifically with respect to the minimum stockholders' equity requirement. The Company announced today that it has submitted information required to demonstrate compliance with the Nasdaq Capital Market's stockholders' equity requirement within the remediation period granted by the Panel.
WARWICK, UK / ACCESS Newswire / April 29, 2026 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced the successful completion of the first phase of industrialization of its GLASO1 safflower platform, following a 2025 campaign that materially exceeded all internal forecasts. Building on previously reported results confirming approximately 45% GLA ("Gamma-linolenic acid") concentration at commercial scale, the Company has now validated not only agronomic and processing performance, but also the industrial-scale handling and availability of high-purity GLA output, marking a critical step toward full commercial deployment.
WARWICK, GB / ACCESS Newswire / April 7, 2026 / Moolec Science Limited, a wholly owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced a significant scientific breakthrough in the production of animal proteins in plants. Through a sponsored research project with one of the most prestigious academic institutions in the United States of America, Moolec has successfully demonstrated the stable expression of bovine myoglobin, a heme-containing protein, within the seeds of the common pea (Pisum sativum).
Moolec Science (NASDAQ: MLEC - Get Free Report) is anticipated to release its results before the market opens on Tuesday, April 14th. Analysts expect Moolec Science to post earnings of ($16.50) per share and revenue of $4.3870 million for the quarter. Moolec Science Stock Performance Shares of MLEC stock opened at $11.44 on Tuesday. Moolec Science